Haemodynamic characteristics before and after the onset of protein losing enteropathy in patients after the Fontan operation

European Journal of Cardio-thoracic Surgery

Volumn 43, Issue 3, 2013, Pages

  Ohuchi, Hideo ^a   Yasuda, Kenji ^a   Miyazaki, Aya ^a   Kitano, Masataka ^a   Sakaguchi, Heima ^a   Yazaki, Satoshi ^a   Tsuda, Etsuko ^a   Yamada, Osamu ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Central venous pressure; Fontan procedure; Haemodynamics; Protein losing enteropathy

Indexed keywords

ALBUMIN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CARVEDILOL; CATECHOLAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; METOPROLOL; PROSTACYCLIN DERIVATIVE; SILDENAFIL; STEROID; WARFARIN;

ADOLESCENT; AORTA PRESSURE; ARTERIAL OXYGEN SATURATION; ARTERIAL PRESSURE; ARTERY RESISTANCE; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CENTRAL VENOUS PRESSURE; CHILD; COIL EMBOLIZATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; FONTAN PROCEDURE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART OUTPUT; HEART VENTRICLE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; LUNG CIRCULATION; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBSTRUCTION; ONE LUNG PULMONARY CIRCULATION; OXYGEN THERAPY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; PULMONARY ARTERIOVENOUS FISTULA; RISK FACTOR; SCHOOL CHILD; STENOSIS; SURVIVOR;

EID: 84873650944     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezs714     Document Type: Article

References (20)

1. Feldt RH, Driscoll DJ, Offord KP, Cha RH, Perrault J, Schaff HV et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1996;112:672-80.
2. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998;115:1063-73.
3. Lenz D, Hambsch J, Schneider P, Häusler HJ, Sauer U, Hess J et al. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit Care 2003;7:185-90.
4. Shimizu T, Nagata S, Fujii T, Takahashi K, Kishiro M, Ohkubo M et al. Enhanced production of interferon-gamma as a possible cause of protein-losing enteropathy after modified Fontan operation. J Pediatr Gastroenterol Nutr 2003;37:504-7.
5. Bode L, Murch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem 2006; 281:7809-15.
6. Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y et al. Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 2008;118: 229-38.
7. Rychik J, Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol 2002;90: 672-4.
8. Rychik J. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis 2007;2:288-300.
9. Ohuchi H, Miyazaki A, Wakisaka Y, Watanabe K, Kishiki K, Yamada O et al. Systemic ventricular morphology-associated increased QRS duration compromises the ventricular mechano-electrical and energetic properties long-term after the Fontan operation. Int J Cardiol 2009;133: 371-80.
10. Ohuchi H, Ono S, Tanabe Y, Fujimoto K, Yagi H, Sakaguchi H et al. Long-term serial aerobic exercise capacity and hemodynamic properties in clinically and hemodynamically good, 'Excellent', Fontan survivors. Circ J 2012;76:195-203.
11. Ohuchi H, Yasuda K, Hasegawa S, Miyazaki A, Takamuro M, Yamada O et al. Influence of ventricular morphology on aerobic exercise capacity in patients after the Fontan operation. J Am Coll Cardiol 2001;37: 1967-74.
12. Ohuchi H, Miyazaki A, Watanabe T, Yamada O, Yagihara T, Echigo S. Hemodynamic deterioration during simulated supraventricular tachycardia in patients after the Fontan operation. Int J Cardiol 2007; 117:381-7.
13. Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006;82:695-700.
14. Ohuchi H, Ikado H, Noritake K, Miyazaki A, Yasuda K, Yamada O. Impact of central venous pressure on cardio-renal interactions in adults with congenital heart disease after biventricular repair. Congenit Heart Dis 2012;10.1111/j.1747-0803.2012.007717.
15. Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 1991;68:819-21.
16. Schumacher KR, Cools M, Goldstein BH, Ioffe-Dahan V, King K, Gaffney D et al. Oral budesonide treatment for protein-losing enteropathy in fontan-palliated patients. Pediatr Cardiol 2011;32:966-71.
17. Senzaki H, Kyo S, Matsumoto K, Asano H, Masutani S, Ishido H et al. Cardiac Resynchronization Therapy in a Patient with Single Ventricle and Intracardiac Conduction Delay. J Thorac Cardiovasc Surg 2004;127: 287-8.
18. Durongpisitkul K, Porter CJ, Cetta F, Offord KP, Slezak JM, Puga FJ et al. Predictors of early- and late-onset supraventricular tachyarrhythmias after Fontan operation. Circulation 1998;98:1099-107.
19. Atz AM, Travison TG, McCrindle BW, Mahony L, Quartermain M, Williams RV et al. Pediatric Heart Network Investigators. Late status of Fontan patients with persistent surgical fenestration. J Am Coll Cardiol 2011;57:2437-43.
20. Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011;21:363-77.